11.01.2015 Views

Final Conference Program - aatod

Final Conference Program - aatod

Final Conference Program - aatod

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Conference</strong> Sessions<br />

Tuesday, October 26, 2010<br />

Tuesday Continental Breakfast<br />

7:30 a.m.–8:30 a.m., Southwest Hall<br />

Sponsored by Reckitt Benckiser<br />

Pharmaceuticals, Inc.<br />

MIDDLE PLENARY SESSION<br />

8:45 a.m.–10:15 a.m.<br />

Addiction, Pharmacology and the Criminal Justice<br />

System: What are the Challenges to Expanding the<br />

Use of Pharmacologic Treatment Interventions for<br />

Opioid Dependent Individuals Under the<br />

Jurisdiction of the Criminal Justice System<br />

International North<br />

Moderator<br />

Speakers<br />

Melody Heaps, President<br />

Emeritus, Treatment<br />

Alternatives for Safer<br />

Communities, Chicago, IL<br />

West Huddleston,<br />

President,<br />

National<br />

Association of<br />

Drug Court<br />

Professionals,<br />

Alexandria, VA<br />

Scott Chavez,<br />

Vice President,<br />

National<br />

Commission on<br />

Correctional<br />

Healthcare,<br />

Chicago, IL<br />

Dawn Bushma,<br />

LCSW, Senior US<br />

Probation<br />

Officer, US<br />

Probation Office,<br />

Chicago, IL<br />

This plenary will be moderated by Melody Heaps, President Emeritus,<br />

Treatment Alternatives for Safer Communities. Despite the fact<br />

that science has confirmed that addiction is a brain disease and not<br />

a question of lack of will power or moral failure, certain public<br />

sectors have been resistant to using medication-assisted treatment.<br />

In particular, the criminal justice system has resisted, and in some<br />

cases prohibited the use of such treatment for addicted individuals.<br />

This plenary will explore the reasons behind such resistance, discuss<br />

models of pharmacological treatments within the justice system, the<br />

challenges treatment systems face in working with the criminal<br />

justice system, and the future of medication-assisted treatment in<br />

the criminal justice system.<br />

10:30 a.m.–12:00 p.m.<br />

WORKSHOP SESSIONS<br />

C1 Alcohol Abuse in Methadone Treatment:<br />

Understanding and Addressing a Serious Problem<br />

International South<br />

Allan J. Cohen, MA, Bay Area Addiction, Research and<br />

Treatment, Inc. (BAART), Los Angeles, CA<br />

Daniel D. George, MPH, Matrix Institute on Addictions, Los<br />

Angeles, CA<br />

Alcohol abuse in methadone maintained patients has proven to be<br />

among the most costly and difficult problems to successfully address<br />

and treat in the opioid treatment program. The costs of this problem<br />

in terms of patient mortality, poor treatment outcomes, staff and<br />

program resources and negative community impact are enormous.<br />

This workshop will present an overview of the problem of alcohol<br />

abuse in methadone maintained patient populations including a<br />

review of past and current research on this issue. We will explore an<br />

array of clinical and programmatic issues related to alcohol abuse<br />

and discuss treatment options.<br />

* Note: Basic Track<br />

AMA PRA Category 1 Credit approved.<br />

C2 An Analysis of Opioid-Addicted Medicaid<br />

Patients in Baltimore City<br />

Continental A<br />

Gregory C. Warren, MA, Baltimore Substance Abuse Systems,<br />

Inc., Baltimore, MD<br />

Utilizing a coordinated public health response, Buprenorphine<br />

medication and innovative clinical and financial processes have<br />

been created to improve access and treatment outcomes for heroin<br />

addicts in Baltimore. There will be three areas of discussion in the<br />

workshop. First, critical lessons learned in how to establish a<br />

buprenorphine induction and stabilization continuum of care will be<br />

discussed. Organizational change and new interagency partnerships<br />

needed to be forged to address the cultural, regulatory and financial<br />

barriers which needed to be overcome. <strong>Final</strong>ly, the presenter will<br />

share Baltimore’s outcomes and preliminary research findings and<br />

whether these changes achieved savings in health care utilization.<br />

C3 The Georgia Strategy for Stigma Reduction<br />

Continental B<br />

Jonathan Connell, MA, Private Clinic, Albany, GA<br />

Stacey Pearce, BS, GPA Treatment of Macon, Inc., Macon, GA<br />

Joelyn Alfred, MS, Opioid Treatment Providers of Georgia,<br />

Norcross, GA<br />

For years, treatment providers quietly provided treatment without<br />

confronting the stigma in our communities. This presentation is<br />

designed to demonstrate the process Opioid Treatment Providers of<br />

Georgia went through to confront the stigma within the state of<br />

Georgia associated with Medication Assisted Treatment. Presenters<br />

16 AATOD National <strong>Conference</strong> | Building Partnerships: Advancing Treatment & Recovery

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!